These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30760105)

  • 41. Anemia and its association with clinical outcome in heart failure patients undergoing cardiac resynchronization therapy.
    Venkateswaran RV; Freeman C; Chatterjee N; Kandala J; Orencole M; Vegh EM; Parks KA; Cowburn PJ; Dec GW; Singh JP; Borgquist R
    J Interv Card Electrophysiol; 2015 Dec; 44(3):297-304. PubMed ID: 26453528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
    Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
    J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.
    Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
    J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.
    Gravning J; Askevold ET; Nymo SH; Ueland T; Wikstrand J; McMurray JJ; Aukrust P; Gullestad L; Kjekshus J;
    Circ Heart Fail; 2014 Jan; 7(1):96-103. PubMed ID: 24284025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
    Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
    Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.
    Kempf T; von Haehling S; Peter T; Allhoff T; Cicoira M; Doehner W; Ponikowski P; Filippatos GS; Rozentryt P; Drexler H; Anker SD; Wollert KC
    J Am Coll Cardiol; 2007 Sep; 50(11):1054-60. PubMed ID: 17825714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart failure subphenotypes based on repeated biomarker measurements are associated with clinical characteristics and adverse events (Bio-SHiFT study).
    de Lange I; Petersen TB; de Bakker M; Akkerhuis KM; Brugts JJ; Caliskan K; Manintveld OC; Constantinescu AA; Germans T; van Ramshorst J; Umans VAWM; Boersma E; Rizopoulos D; Kardys I
    Int J Cardiol; 2022 Oct; 364():77-84. PubMed ID: 35714717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease.
    Fluschnik N; Ojeda F; Zeller T; Jørgensen T; Kuulasmaa K; Becher PM; Sinning C; Blankenberg S; Westermann D
    PLoS One; 2018; 13(5):e0197497. PubMed ID: 29771963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of diabetes on the predictive value of heart failure biomarkers.
    Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
    Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.
    Linde C; Daubert C; Abraham WT; St John Sutton M; Ghio S; Hassager C; Herre JM; Bergemann TL; Gold MR;
    Circ Heart Fail; 2013 Nov; 6(6):1180-9. PubMed ID: 24014828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study.
    Maisel A; Xue Y; Shah K; Mueller C; Nowak R; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand IS; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
    Circ Heart Fail; 2011 Sep; 4(5):613-20. PubMed ID: 21765124
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population.
    Cauwenberghs N; Ravassa S; Thijs L; Haddad F; Yang WY; Wei FF; López B; González A; Díez J; Staessen JA; Kuznetsova T
    J Am Heart Assoc; 2019 Jan; 8(2):e010430. PubMed ID: 30638123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.
    Aimo A; Januzzi JL; Vergaro G; Ripoli A; Latini R; Masson S; Magnoli M; Anand IS; Cohn JN; Tavazzi L; Tognoni G; Gravning J; Ueland T; Nymo SH; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Tentzeris I; Tang WHW; Grodin J; Passino C; Emdin M
    Circulation; 2018 Jan; 137(3):286-297. PubMed ID: 29335288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.